Alexion Pharmaceuticals, Inc. (ALXN)

182.50
Prev Close 182.50
Day Low/High 0.00 / 0.00
52 Wk Low/High 99.91 / 187.45
Exchange
Div & Yield N.A. (N.A)

Rules of the Game: No Slowdown in Health Care

Some growth leaders in the sector are getting technical support.

Off the Charts

Off the Charts

Updating our current trade ideas.

Alexion Looks Promising

Alexion Looks Promising

The stock seems liable to reenter its uptrend, so here's how to play it.

A Blueprint for Highflier Stability

A Blueprint for Highflier Stability

Cautionary tales that the IPO window might be closing at last.

Off the Charts

Off the Charts

Intel  breaks above our target on Piper Jaffray upgrade.

Off the Charts

Off the Charts

Ford rallies after March auto sales blow past Street view, surpassing our target.

Off the Charts

Off the Charts

Alaska Air is trading above all key moving averages with a healthy uptrend since July.

Who's Getting Busy Living?

Who's Getting Busy Living?

These types of companies are winners today.

Alexion downgraded at Goldman

Off the Charts

Off the Charts

Maintain a stock-specific approach until a clearer trend develops.

Off the Charts

Off the Charts

Most investors seem to be in wait-and-see mode due to overall policy confusion.

Off the Charts

Off the Charts

Depending on your risk appetite, it makes sense to keep it light heading into this weekend.

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.

Cramer: Why Alexion is Ripe for Deal

Cramer: Why Alexion is Ripe for Deal

Jim Cramer looks at the pop in Alexion on rumors of Roche deal, and why this deal makes sense.

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...

Off the Charts

Off the Charts

We see a lot of short squeezes as money rotates into laggard groups. 

Biotech Makes a Comeback

Biotech Makes a Comeback

Just a natural change in leadership.

Market Takes Aim at Historic Highs Once Again

Market Takes Aim at Historic Highs Once Again

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Off the Charts

Off the Charts

Upward momentum is lagging.

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

Two Long Setups in the Pharma Sector

Two Long Setups in the Pharma Sector

Charts of Actavis and Alexion show a combination of positive technical factors.

Alexion downgraded at Lazard

Rules of the Game: Cranking Out the Green

Rules of the Game: Cranking Out the Green

Here's another batch of names with impressive free cash flow, a crucial metric.